Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Other Non Operating Income (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Other Non Operating Income for 9 consecutive years, with -$117000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 400.0% to -$117000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $58000.0, a 111.22% increase, with the full-year FY2025 number at $58000.0, up 111.22% from a year prior.
  • Other Non Operating Income was -$117000.0 for Q4 2025 at Akebia Therapeutics, down from -$10000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $2.5 million in Q4 2022 to a low of -$1.4 million in Q3 2021.
  • A 5-year average of $188785.7 and a median of $14500.0 in 2024 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: plummeted 448.05% in 2021, then skyrocketed 604.35% in 2022.
  • Akebia Therapeutics' Other Non Operating Income stood at -$1.4 million in 2021, then skyrocketed by 275.68% to $2.5 million in 2022, then tumbled by 101.72% to -$43000.0 in 2023, then skyrocketed by 190.7% to $39000.0 in 2024, then tumbled by 400.0% to -$117000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Other Non Operating Income are -$117000.0 (Q4 2025), -$10000.0 (Q3 2025), and $185000.0 (Q2 2025).